Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Anderson, William F.; Luo, Sheng; Chatterjee, Nilanjan; Rosenberg, Philip S.; Matsuno, Rayna K.; Goodman, Marc T.; Hernandez, Brenda Y.; Reichman, Marsha E.; Dolled‐Filhart, Marisa; O’Regan, Ruth; Perou, Charles M.; Jatoi, Ismail; Cartun, Richard W.; Sherman, Mark E.

doi:10.1007/s10549-008-9918-3

Cited by 36 publications

(42 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tissue microarray (TMA) studies, widely used for high throughput testing of breast cancer biomarkers, can be significantly catalyzed and eased with digital microscopy, particularly when supported with dedicated software tools for intelligent data management [1,7,11]. TMAs can be used for saving diagnostic budget of routine HER-2 assessment by concentrating IHC and FISH in once a week runs.…”

Section: Diagnostics and Researchmentioning

confidence: 99%

The Potential of Digital Microscopy in Breast Pathology

Krenács

Zsakovics

Diczhazi

et al. 2008

Pathol. Oncol. Res.

View full text Add to dashboard Cite

The rapidly evolving field of digital microscopy supports the efficient exploitation of inherent information from stained glass slides to offer widespread utilization in breast histopathology. Digital image signals can be accurately measured, integrated into databases and shared through computer networks. Therefore, digital microscopy can boost telepathology-consultation, gradual- and postgradual teaching, proficiency testing, intra- and interlaboratory validation of biomarker screening interpretation, and automated image analysis of biomarker expression for both diagnostics and research applications. This is a brief highlight of the potential of digital microscopy in breast pathology applications.

show abstract

Section: Diagnostics and Researchmentioning

confidence: 99%

The Potential of Digital Microscopy in Breast Pathology

Krenács

Zsakovics

Diczhazi

et al. 2008

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Many studies examined SEER-linked biospecimens for the leading malignant cancer diagnoses: female breast (9, 23, 24, 27, 32, 37), colon and rectum (18, 29, 30, 38), lung (10), and prostate(16) cancers. Other studies focused on cancer types responsible for an increasing proportion of cancer deaths, including pancreas (8, 21, 35, 36) and liver cancer (19, 22, 33).…”

Section: Resultsmentioning

confidence: 99%

“…FFPE cores also were used to construct tissue microarrays (TMA) (8, 9, 18, 21, 22, 24, 32, 35, 36) and multiple tumor block arrays (26, 28). In one study, FFPE tissues were used for pathology review, and frozen normal tissues were used for DNA methylation studies (33).…”

Section: Resultsmentioning

confidence: 99%

“…Biospecimen research topics (Table 1) included assessment of immunohistochemical markers (8, 9, 18, 21–23, 30, 32, 35, 36) and genetic sequences (10–17, 19, 20, 26, 28, 29, 31, 34). Several studies examined histopathology markers (24, 25, 27, 37) and DNA methylation in cancer tissue (33, 38).…”

Section: Resultsmentioning

confidence: 99%

“…Several studies reported cancer subtype distributions across racial and ethnic populations (9, 12–14, 17, 18, 20–22, 24, 26, 35–38). Biospecimens also were used to study molecular subtype distributions in the populations for cancer of the breast (9) and colon and rectum (30), and for non-Hodgkin lymphoma (11–13), including subtypes of diffuse large B-cell lymphoma (28) and Burkitt lymphoma (26).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

SEER Cancer Registry Biospecimen Research: Yesterday and Tomorrow

Altekruse

Rosenfeld

Carrick

et al. 2014

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

The National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) registries have been a source of biospecimens for cancer research for decades. Recently, registry-based biospecimen studies have become more practical, with the expansion of electronic networks for pathology and medical record reporting. Formalin-fixed paraffin-embedded specimens are now used for next-generation sequencing and other molecular techniques. These developments create new opportunities for SEER biospecimen research. We evaluated 31 research articles published during 2005–2013 based on author confirmation that these studies involved linkage of SEER data to biospecimens. Rather than providing an exhaustive review of all possible articles, our intent was to indicate the breadth of research made possible by such a resource. We also summarize responses to a 2012 questionnaire that was broadly distributed to the NCI intra- and extramural biospecimen research community. This included responses from 30 investigators who had used SEER biospecimens in their research. The survey was not intended to be a systematic sample, but instead to provide anecdotal insight on strengths, limitations, and the future of SEER biospecimen research. Identified strengths of this research resource include biospecimen availability, cost, and annotation of data, including demographic information, stage, and survival. Shortcomings include limited annotation of clinical attributes such as detailed chemotherapy history and recurrence, and timeliness of turnaround following biospecimen requests. A review of selected SEER biospecimen articles, investigator feedback, and technological advances reinforced our view that SEER biospecimen resources should be developed. This would advance cancer biology, etiology, and personalized therapy research.

show abstract

Differences in IGF‐axis protein expression and survival among multiethnic breast cancer patients

et al. 2015

View full text Add to dashboard Cite

There is limited knowledge about the biological basis of racial/ethnic disparities in breast cancer outcomes. Aberrations in IGF signaling induced by obesity and other factors may contribute to these disparities. This study examines the expression profiles of the insulin-like growth factor (IGF)-axis proteins and the association with breast cancer survival across a multiethnic population. We examined the expression profiles of the IGF1, IGF1R, IGFBP2 (IGF-binding proteins), and IGFBP3 proteins in breast tumor tissue and their relationships with all-cause and breast cancer-specific survival up to 17 years postdiagnosis in a multiethnic series of 358 patients in Hawaii, USA. Native Hawaiians, Caucasians, and Japanese were compared. Covariates included demographic and clinical factors and ER/PR/HER2 (estrogen receptor/progesterone receptor/human epidermal growth factor receptor-2) status. In Native Hawaiian patients, IGFBP2 and IGFBP3 expression were each independently associated with overall and breast cancer mortality (IGFB2: HRmort = 10.96, 95% CI: 2.18–55.19 and HRmort = 35.75, 95% CI: 3.64–350.95, respectively; IGFBP3: HRmort = 5.16, 95% CI: 1.27–20.94 and HRmort = 8.60, 95% CI: 1.84–40.15, respectively). IGF1R expression was also positively associated with all-cause mortality in Native Hawaiians. No association of IGF-axis protein expression and survival was observed in Japanese or Caucasian patients. The interaction of race/ethnicity and IGFBP3 expression on mortality risk was significant. IGF-axis proteins may have variable influence on breast cancer progression across different racial/ethnic groups. Expression of binding proteins and receptors in breast tumors may influence survival in breast cancer patients by inducing aberrations in IGF signaling and/or through IGF-independent mechanisms. Additional studies to evaluate the role of the IGF-axis in breast cancer are critical to improve targeted breast cancer treatment strategies.

show abstract

Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program

Cited by 36 publications

References 26 publications

The Potential of Digital Microscopy in Breast Pathology

The Potential of Digital Microscopy in Breast Pathology

SEER Cancer Registry Biospecimen Research: Yesterday and Tomorrow

Differences in IGF‐axis protein expression and survival among multiethnic breast cancer patients

Contact Info

Product

Resources

About